All News

Pharmacists are resilient, community-focused professionals who played a pivotal role in navigating the unprecedented challenges of the COVID-19 pandemic.

Jennifer Zilka and Kyle Pudenz, DBA, from Cencora joined Drug Topics to discuss the role of independent pharmacies in addressing pharmacy deserts across the US.

The top reported barriers to providing buprenorphine included regulatory and administrative, operational and attitudinal, and patient-related challenges.

On both an individual and societal level, researchers explored how social, cultural, and ethnic determinants impact the treatment and management of obesity.

As pharmacists move away from opioids in pain management, researchers present the use of supplemental OTC products to assist patients’ acute pain.

Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.

A conversation with Nicole Cieri-Hutcherson, PharmD, BCPS, MSCP, FCCP, clinical associate professor at University at Buffalo.

The most commonly reported symptoms of long COVID include neurological, muscular, respiratory, and psychological.

Using a novel pharmacy vulnerability index, researchers identified US regions at the most risk of becoming pharmacy deserts.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.

George Van Antwerp, MBA, senior vice president of Product Innovation and Strategic Planning at Prime Therapeutics, discusses how pharmacists can help patients decide which digital tools are best for them.

A new report from the American Economic Liberties Project presents the continued challenges pharmacies face since Congress’ failure to pass PBM reform at the end of 2024.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed the common trends in GLP-1 use she’s seen amongst her patients as well as her extensive experience working with this medication class.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

This year’s meeting will take place from March 21 to 24 in Nashville, Tennessee.

Additional data shows that an investigational drug, given every 4 months with Apretude, kept viral levels suppressed for patients who were already on stable treatment.

These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

Approximately, 62% of respondents stated that the number of active drug shortages could potentially increase by more than 25% within the next 5 years.

With minimal pharmacological treatments coming to market for chronic pain, researchers have explored new technologies for advancing pain treatment across the globe.

US Senators on both sides of the aisle came together to announce the Protecting Pharmacies in Medicaid Act.

A conversation with Todd Bertoch, MD, chief medical officer for pain research at CenExel and an investigator on the ALLEVIATE-2 trial.

Ensitrelvir demonstrated a 67% relative risk reduction of developing symptomatic COVID-19 in household contact patients.

Deucravacitinib (Sotyktu) also demonstrates improvements in signs and symptoms, extra-articular manifestations, and patient-reported outcomes.

Patients aged 12 to under 18 saw clinically meaningful regrowth on the scalp, eyebrow, and eyelashes with both high-dose and low-dose treatment.

Representatives from Cencora’s Good Neighbor Pharmacy Network discussed legislation created to improve declining pharmacy rates and who is accountable for addressing pharmacy deserts.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.